Wipro and Pandorum Technologies, a Bengaluru-based biotechnology company, have announced a long-term partnership to develop technologies that reduce the time-to-market period and improve patient outcomes during R&D and clinical trials of regenerative medicine. The partnership will use Wipro Holmes’ AI platform and Pandorum’s experience in tissue engineering and regenerative medicine. 

The first project that the partnership will revolve around is bio-engineered liquid corneas and then gradually move towards developing products on lung and liver regenerative tissues. 

Wipro Holmes will predict and improve the effectiveness of therapeutics, offer insights to make specific formulae and help study design in medicine. 

“By embracing digital technologies such as artificial intelligence, life sciences organisations can accelerate innovation, transform business processes and fuel growth. In R&D, AI is particularly valuable to rapidly discover new formulations, expedite therapeutic development and bring life-saving therapies to market faster, thereby positively influencing human health,” said Rajan Kohli, president and managing partner at IDeaS, Wipro Limited.

Co-founder and CEO of Pandorum, Tuhin Bhowmick, noted, “We’re living in a time of unprecedented progress in biology, data science and machine learning. Pandorum is building a framework to converge these three fields, in order to harness the potential of tissue reprogramming to the fullest and address global unmet clinical needs, such as corneal blindness and liver diseases.”